

Amendments to the Specification

Please replace the paragraph at p. 6, lines 11-25 with the following replacement paragraph:

O- α -acyloxyalkyl ethers of Formula I and their pharmaceutically useful salts and hydrates are useful for the biological and pharmacological activities for which venlafaxine and its salts are known in the art. These O- α -acyloxyalkyl ethers may be used in treating or inhibiting central nervous system disorders, including depression, anxiety, panic disorder, post-traumatic stress disorder, late luteal phase dysphoric disorder (also known as pre-menstrual syndrome), attention deficit disorder, with and without hyperactivity, obsessive compulsive disorder, social phobias, generalized anxiety disorder, bulimia nervosa, Gilles de la Tourette Syndrome, Shy Drager Syndrome, vasomotor flushing, drug and alcohol addiction, cocaine addiction, sexual dysfunction (including premature ejaculation), borderline personality disorder, chronic fatigue syndrome, fibromyalgia, urinary incontinence, chronic obstructive pulmonary disorder, migraine, Raynaud's Syndrome, postherpetic neuralgia, pain, chronic back pain, and others. These compounds are also useful in the inducement of cognition enhancement, treatment of obesity and in regimens for cessation of smoking or other tobacco uses.